Age: 49.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: COVID-19, Skin disorder, Vaccination failure
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of SKIN DISORDER (Skin did not clear up), COVID-19 (COVID-19) and VACCINATION FAILURE (Vaccination failure) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis and Rheumatoid arthritis. Concurrent medical conditions included Psoriatic arthritis and Rheumatoid arthritis (Moderate to severe rheumatoid arthritis). Concomitant products included INFLUENZA VACCINE for an unknown indication. On 13-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. On 01-Jul-2022, the patient experienced COVID-19 (COVID-19) and VACCINATION FAILURE (Vaccination failure). On an unknown date, the patient experienced SKIN DISORDER (Skin did not clear up). At the time of the report, SKIN DISORDER (Skin did not clear up) and VACCINATION FAILURE (Vaccination failure) outcome was unknown and COVID-19 (COVID-19) was resolving. It was reported that on unknown dates, the patient experienced skin did not clear up. felt overdosed while Humira was taken and COVID-19 hindered the effect of treatment. On 01 Jul 2022, the patient experienced COVID-19 hindered the effect of treatment. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. No treatment information was reported. Company Comment: This is a Spontaneous case reported by a consumer, concerning a 50-year-old female patient, with no relevant medical history, who experienced the unexpected and non-serious of COVID-19, which occurred approximately 20 days after the second dose of mRNA-1273 vaccine, which was administered in an appropriate schedule of vaccination. Hence, Vaccination failure was noted. Co-suspect product included non-company product Adalimumab for psoriatic arthritis and rheumatoid arthritis. No information disclosed about diagnostic tests performed or treatments received. At the time of the report, COVID-19 was resolving. The benefit-risk relationship of mRNA-1273 vaccine, is not affected by this report.; Sender's Comments: This is a Spontaneous case reported by a consumer, concerning a 50-year-old female patient, with no relevant medical history, who experienced the unexpected and non-serious of COVID-19, which occurred approximately 20 days after the second dose of mRNA-1273 vaccine, which was administered in an appropriate schedule of vaccination. Hence, Vaccination failure was noted. Co-suspect product included non-company product Adalimumab for psoriatic arthritis and rheumatoid arthritis. No information disclosed about diagnostic tests performed or treatments received. At the time of the report, COVID-19 was resolving. The benefit-risk relationship of mRNA-1273 vaccine, is not affected by this report.